Dystonia
An attitude or posture due to the co-contraction of agonists and antagonist muscles in one region of the body. It most often affects the large axial muscles of the trunk and limb girdles. Conditions which feature persistent or recurrent episodes of dystonia as a primary manifestation of disease are referred to as DYSTONIC DISORDERS. (Adams et al., Principles of Neurology, 6th ed, p77)
Subtype terms (1)
More specific conditions that are subtypes of Dystonia in the MeSH hierarchy.
- Torticollis
13 drugs (9 approved, 4 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (3)
Phase 3 trials (3)
Phase 2 trials (7)
Phase 1 trials (4)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (14)
- Solstice Neurosciences
- Ipsen
- Allergan
- Merz
- American Academy of Neurology
- Chulalongkorn University
- Gottfried Wilhelm Leibniz Universität Hannover
- Seoul National University
- Taoyuan General Hospital
- University of Florida
- Columbia University
- Tel Aviv University
- University of California, San Francisco
- Government of Taiwan
Organization Involved with Phase 3 Indications (11)
Organization Involved with Phase 2 Indications (20)
- Eisai
- ASIS Corporation
- BCN Peptides
- Teva
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of Pennsylvania
- Emory University
- Stanford University
- University of South Florida
- University of Southern California
- University of Toronto
- Icahn School of Medicine at Mount Sinai
- Taro Pharmaceuticals
- University of Western Ontario
- Dystonia Study Group
- United Cerebral Palsy Foundation
- Dystonia Medical Research Foundation
- Don and Linda Carter Foundation
- Crowley Carter Foundation
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (3)